Search Results for "Sunitinib"

12:23 EDT 8th October 2015 | BioPortfolio

Matching Channels


Matching News

Chromosomal Changes Predict Clinical Response to Sunitinib in RCC

Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict CR to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).

Celldex begins Phase I/II trial of varlilumab-sunitinib combination to treat CC-RCC

US-based Celldex Therapeutics has started an open-label, Phase I/II safety and tolerability trial evaluating the investigational combination of varlilumab and sunitinib (Sutent) in patients with metas...

Kidney cancer: Sunitinib: 2/1 is superior to 4/2

Kidney cancer: Effect of sorafenib and sunitinib on cardiac function

Kidney cancer: Sunitinib is effective in a subset of patients with mRCC

Kidney cancer: Trebananib plus sunitinib improves survival outcomes

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

Matching PubMed Articles

AXL as a modulator of sunitinib response in glioblastoma cell lines.

Receptor tyrosine kinase (RTK) targeted therapy has been explored for glioblastoma treatment. However, it is unclear which RTK inhibitors are the most effective and there are no predictive biomarkers ...

Sunitinib - ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver and kidney in male and female mice differently.

Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.

The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed t...

Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): A systematic review of the literature.

The randomized phase III trial of sunitinib versus interferon Alfa provided level-A evidence for the use of sunitinib in advanced clear cell renal cell carcinoma (RCC). This systematic literature revi...

Search Whole site using Google


Advertisement Advertisement